Optimizing the antiretroviral treatment focusing on long-term effectiveness and a person-centered approach. Consensus Guidance Using a Delphi Process.
HIV
comorbidities
durability
immune activation
inflammation
quality of life
Journal
The new microbiologica
ISSN: 1121-7138
Titre abrégé: New Microbiol
Pays: Italy
ID NLM: 9516291
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
22
01
2024
accepted:
22
01
2024
medline:
22
1
2024
pubmed:
22
1
2024
entrez:
22
1
2024
Statut:
ppublish
Résumé
Definitive data on the long-term success of the latest antiretroviral therapy (ART) strategies are still lacking. A panel of infectious diseases specialists was convened to develop a consensus on how to tailor and follow ART over time. Panelists used a Delphi technique to develop a list of statements describing preferred management approaches for ART and patient monitoring and quality of life evaluation. Ninety infectious diseases specialists from several Infectious Diseases Centers in Italy participated in the consensus process. A consensus was reached on virological and immunological parameters to use to monitor long-term efficacy of antiretroviral treatment, while there was no consensus on the use of specific inflammation and immune-activation markers in clinical routine. The panel agreed on the need for an antiretroviral treatment with the lowest impact on bone, kidney and cardiovascular toxicity and on the utility of quality-of-life monitoring during the standard follow up of people living with HIV. The consensus statements developed by a panel of infectious diseases specialists may provide guidance to practitioners for a person-centered approach aimed at obtaining long-term virological and clinical success for people living with HIV.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM